PE20231050A1 - Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso - Google Patents

Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso

Info

Publication number
PE20231050A1
PE20231050A1 PE2023001172A PE2023001172A PE20231050A1 PE 20231050 A1 PE20231050 A1 PE 20231050A1 PE 2023001172 A PE2023001172 A PE 2023001172A PE 2023001172 A PE2023001172 A PE 2023001172A PE 20231050 A1 PE20231050 A1 PE 20231050A1
Authority
PE
Peru
Prior art keywords
eribulin
methods
drug conjugates
based antibody
linked
Prior art date
Application number
PE2023001172A
Other languages
English (en)
Inventor
Earl F Albone
Xin Cheng
Daniel W Custar
Keiji Furuuchi
Utpal Majumder
Toshimitsu Uenaka
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20231050A1 publication Critical patent/PE20231050A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion que comprende -L-D, en donde D es eribulina; y L es un enlazador escindible unido covalentemente a D, en donde el enlazador escindible comprende una unidad espaciadora PEG unida a valina (Val) unida a citrulina (Cit), en donde la unidad espaciadora PEG comprende -(PEG)m- y m es un entero entre 1 y 10, y en donde Cit esta covalentemente unida a eribulina directamente o a traves de una unidad espaciadora adicional opcional.
PE2023001172A 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso PE20231050A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302562P 2016-03-02 2016-03-02
PCT/US2017/020529 WO2017151979A1 (en) 2016-03-02 2017-03-02 Eribulin-based antibody-drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
PE20231050A1 true PE20231050A1 (es) 2023-07-11

Family

ID=58347964

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2023001172A PE20231050A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
PE2023001171A PE20231049A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
PE2018001578A PE20181953A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2023001171A PE20231049A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
PE2018001578A PE20181953A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso

Country Status (34)

Country Link
US (4) US10548986B2 (es)
EP (2) EP3824909A1 (es)
JP (5) JP6599019B2 (es)
KR (4) KR102456433B1 (es)
CN (4) CN114272389B (es)
AR (3) AR107787A1 (es)
AU (2) AU2017225982B2 (es)
BR (1) BR112018067379A2 (es)
CA (1) CA3013791A1 (es)
CL (3) CL2018002456A1 (es)
CO (1) CO2018008667A2 (es)
CY (1) CY1124628T1 (es)
DK (1) DK3423105T3 (es)
ES (1) ES2880402T3 (es)
HR (1) HRP20211125T1 (es)
HU (1) HUE054726T2 (es)
IL (2) IL292946B1 (es)
JO (3) JOP20170053B1 (es)
LT (1) LT3423105T (es)
MA (1) MA45280B1 (es)
MD (1) MD3423105T2 (es)
MX (4) MX2018010562A (es)
MY (1) MY189113A (es)
PE (3) PE20231050A1 (es)
PH (1) PH12018501847A1 (es)
PL (1) PL3423105T3 (es)
PT (1) PT3423105T (es)
RS (1) RS62108B1 (es)
RU (2) RU2754369C2 (es)
SG (2) SG10202007520WA (es)
SI (1) SI3423105T1 (es)
TW (3) TW202408592A (es)
UA (1) UA125024C2 (es)
WO (1) WO2017151979A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
MX2018000305A (es) * 2015-06-24 2018-03-14 Japan Chem Res Anticuerpo anti-receptor de transferrina humana que penetra la barrera hematoencefalica.
JP6914193B2 (ja) 2015-06-24 2021-08-04 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
EP3560958A4 (en) 2016-12-26 2020-08-12 JCR Pharmaceuticals Co., Ltd. NEW ANTIBODY ANTI-RECEPTOR OF HUMAN TRANSFERRIN CAPABLE OF PENETRATING THE HEMATOENCEPHALIC BARRIER
PL3606928T3 (pl) 2017-04-05 2023-02-06 President And Fellows Of Harvard College Związek makrocykliczny i jego zastosowania
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CA3081539A1 (en) * 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
CN117924310A (zh) 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途
BR112020024551A2 (pt) 2018-06-01 2021-03-02 Eisai R&D Management Co., Ltd. métodos para usar moduladores de splicing
EP3801632A1 (en) * 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
TW202019487A (zh) * 2018-08-06 2020-06-01 日商第一三共股份有限公司 抗體-藥物結合物及微管蛋白抑制劑之組合
JOP20210159A1 (ar) * 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
MX2022005221A (es) * 2019-11-07 2022-06-08 Eisai R&D Man Co Ltd Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
US20230074385A1 (en) 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
KR20220130160A (ko) * 2020-01-22 2022-09-26 상하이 센후이 메디슨 컴퍼니 리미티드 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
CN113274507A (zh) * 2020-02-20 2021-08-20 亚飞（上海）生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
KR20230020441A (ko) 2020-06-05 2023-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-bcma 항체-약물 컨쥬게이트 및 이용 방법
WO2022031150A1 (ko) * 2020-08-07 2022-02-10 주식회사 피노바이오 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
EP4210751A1 (en) * 2020-09-11 2023-07-19 Alexion Pharmaceuticals, Inc. Anti-ceruloplasmin antibodies and uses thereof
CN116390733A (zh) * 2020-09-28 2023-07-04 纳夫罗根公司 用于治疗癌症的替代性格式化的抗间皮素抗体的组合物和用途
WO2022082068A1 (en) * 2020-10-18 2022-04-21 Ardeagen Corporation Anti-msln binding agents, conjugates thereof and methods of using the same
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
CA3215049A1 (en) * 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
US20240269315A1 (en) * 2021-06-02 2024-08-15 Bio-Thera Solutions, Ltd. Drug conjugate and use thereof
AU2022316425A1 (en) * 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
EP4385522A1 (en) * 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Microtubule inhibitor-based antibody-drug conjugate
CN117881431A (zh) * 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
WO2023041007A1 (zh) * 2021-09-16 2023-03-23 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物及其组合物和用途
WO2023055376A1 (en) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof
TW202317088A (zh) * 2021-10-14 2023-05-01 大陸商江蘇恒瑞醫藥股份有限公司 艾日布林衍生物的製備方法
EP4431521A1 (en) * 2021-12-01 2024-09-18 Shanghai Institute of Biological Products Co., Ltd. Antibody-drug conjugate and use thereof
WO2023103854A1 (zh) * 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
WO2023124963A1 (zh) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用
CN118591394A (zh) * 2022-01-28 2024-09-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
WO2023143320A1 (zh) * 2022-01-28 2023-08-03 博瑞生物医药（苏州）股份有限公司 用于制备抗体药物偶联物的连接子、化合物及用途
CN118647408A (zh) * 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
IL314828A (en) 2022-03-11 2024-10-01 Mablink Bioscience Antibody-drug conjugates and their uses
WO2023200814A1 (en) * 2022-04-12 2023-10-19 Eisai R & D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2023198079A1 (zh) * 2022-04-12 2023-10-19 百奥泰生物制药股份有限公司 治疗her2阳性实体瘤的方法
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof
CN117917248A (zh) * 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物
WO2024107780A2 (en) * 2022-11-14 2024-05-23 Cornell University Anionically functionalized polypeptides, and methods of making same and uses thereof
WO2024153123A1 (zh) * 2023-01-17 2024-07-25 成都百利多特生物药业有限责任公司 一种艾日布林类药物的偶联物
WO2024153224A1 (zh) * 2023-01-19 2024-07-25 江苏恒瑞医药股份有限公司 一种含艾日布林衍生物药物偶联物的药物组合物
WO2024173281A1 (en) * 2023-02-13 2024-08-22 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug conjugate for cancer treatment

Family Cites Families (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
US6019963A (en) 1998-11-20 2000-02-01 D.S.C. Products, Inc. Deodorizing composition containing tea tree and eucalyptus oils
US7109019B2 (en) 1999-01-06 2006-09-19 The Regents Of The University Of California Gene cluster for production of the enediyne antitumor antibiotic C-1027
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20050171014A1 (en) 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
US7659241B2 (en) * 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
JP2004119755A (ja) 2002-09-27 2004-04-15 Alps Electric Co Ltd 磁気検出素子及びその製造方法
US20040071540A1 (en) 2002-10-15 2004-04-15 Lucas Philip J. Disposable/recyclable pallet system and method
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US6997024B2 (en) 2003-10-01 2006-02-14 Truth Hardware Corporation Pull door lock
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP1716179A2 (en) 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
US7117807B2 (en) 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
EP1778298A4 (en) 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
AU2005247346A1 (en) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
USRE46965E1 (en) 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1828776A4 (en) 2004-12-09 2010-03-17 Eisai R&D Man Co Ltd TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
GB0515025D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1948241B1 (en) 2005-08-19 2014-03-05 Endocyte, Inc. Multi-drug ligand conjugates
EP1926757B1 (en) 2005-09-14 2012-02-22 UCB Pharma, S.A. Antibody-comb polymer conjugate
WO2007064691A1 (en) 2005-12-02 2007-06-07 Nabil Habib Lab Treatment of cancer and other diseases
EP2021502A4 (en) 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US20150030534A1 (en) 2013-07-26 2015-01-29 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US20140037539A1 (en) 2012-07-27 2014-02-06 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
EP1977765A1 (en) 2007-04-03 2008-10-08 Diatos Peptide prodrugs
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US8937161B2 (en) * 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
JP5065228B2 (ja) 2007-10-30 2012-10-31 富士通株式会社 携帯端末装置
PL2842575T3 (pl) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Koniugaty aurystatyny lek łącznik
WO2009121031A1 (en) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
EP2321422A4 (en) 2008-07-08 2013-06-19 Abbvie Inc PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
CN102149690A (zh) 2008-09-12 2011-08-10 参天制药株式会社 含有具有导入了磺酸酯结构的苯基作为取代基的新型1，2，3，4-四氢喹喔啉衍生物的糖皮质激素受体激动剂
NZ593314A (en) 2008-12-04 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
US20140339088A1 (en) 2009-03-09 2014-11-20 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
RU2011148913A (ru) 2009-05-01 2013-06-10 Эбботт Лэборетриз Иммуноглобулин с двумя вариабельными доменами и его применение
US8686520B2 (en) * 2009-05-29 2014-04-01 International Business Machines Corporation Spin-torque magnetoresistive structures
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102573909A (zh) * 2009-08-15 2012-07-11 霍夫曼-拉罗奇有限公司 抗血管发生疗法用于治疗先前治疗过的乳腺癌
SG178602A1 (en) * 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US9181162B2 (en) 2010-03-24 2015-11-10 Ohio University Compositions and methods for glucose transport inhibition
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
EP2582728B1 (en) 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
EP2613810B9 (en) 2010-09-07 2016-02-17 Johannes Kepler Universität Linz Biodegradable, water soluble and ph responsive poly(organo)phosphazenes
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012075361A2 (en) 2010-12-02 2012-06-07 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
WO2012106559A1 (en) 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2680839A1 (en) 2011-03-02 2014-01-08 Morphotek, Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
WO2012118978A1 (en) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
CN103502218B (zh) 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
SG10201602147YA (en) 2011-03-18 2016-05-30 Eisai R&D Man Co Ltd Methods And Compositions For Predicting Response To Eribulin
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2012145098A1 (en) 2011-04-21 2012-10-26 Saint Louis University Use of adenosine a3 receptor agonists for treatment of neuropathic pain
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
BR112013030372A2 (pt) 2011-05-27 2016-08-30 Ambrx Inc composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural
WO2012170640A1 (en) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy
JP5926374B2 (ja) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
PT2739649T (pt) 2011-08-05 2018-01-03 Bioasis Technologies Inc Fragmentos de p97 com atividade de transferência
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
WO2013086634A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
AU2012363334B2 (en) 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013130093A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
KR20190134832A (ko) 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
IN2014MN02106A (es) 2012-03-30 2015-09-11 Alphora Res Inc
WO2013152034A1 (en) 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
AU2013263337A1 (en) 2012-05-15 2014-12-04 Diatech Oncology Tumor cell isolation/purification process and methods for use thereof
JP6239597B2 (ja) 2012-05-15 2017-11-29 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 薬物コンジュゲート、コンジュゲーション方法およびその使用
US10800856B2 (en) 2012-06-07 2020-10-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
EP4406612A3 (en) 2012-06-19 2024-10-16 Ambrx, Inc. Anti-cd70 antibody drug conjugates
EP2866795A4 (en) 2012-06-29 2016-01-27 Univ New York State Res Found POLYENOLZIN BINDER FOR THE ACTIVE PROMOTION OF THE INACTIVATION OF CANCER STRAIN CELLS AND FOR THE POTENTIATING OF CYTOTOXIC ANTITUMOROUS SUBSTANCES
CA2877378A1 (en) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
AU2012385228B2 (en) 2012-07-12 2016-10-06 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
WO2014047199A1 (en) 2012-09-19 2014-03-27 The Research Foundation For The State University Of New York Novel prodrugs for selective anticancer therapy
JP6234466B2 (ja) 2012-10-04 2017-11-22 エービー サイエンス 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用
WO2014058317A1 (en) 2012-10-10 2014-04-17 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods and means for predicting resistance to anti-cancer treatment
CN103775148A (zh) 2012-10-22 2014-05-07 张玉良 自冷式热力做功方法
LT3912642T (lt) 2012-10-23 2023-07-25 Synaffix B.V. Modifikuotas antikūnas, antikūno konjugatas ir jų gamybos būdas
EP2917195B9 (en) 2012-11-05 2018-05-30 Pfizer Inc Spliceostatin analogs
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2925318A4 (en) 2012-12-03 2016-07-13 Calithera Biosciences Inc TREATMENT OF CANCER WITH HETEROCYCLIC GLUTAMINASE INHIBITORS
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
WO2014096551A1 (en) 2012-12-21 2014-06-26 Glykos Finland Oy Linker-payload molecule conjugates
US20150182634A1 (en) 2012-12-28 2015-07-02 Cody P. Coyne Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
US20140205681A1 (en) 2013-01-19 2014-07-24 New York University HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION
CA2898329A1 (en) 2013-01-19 2014-07-24 New York University Oligooxopiperazines for p53 reactivation
KR102554628B1 (ko) 2013-02-01 2023-07-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
WO2014121235A2 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
WO2014124329A1 (en) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
JP6382231B2 (ja) 2013-02-22 2018-08-29 ユニバーシティ オブ ヒューストンＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈｏｕｓｔｏｎ 神経保護剤としてのホスファプラチン
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
AU2014230735B2 (en) * 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PT2968294T (pt) 2013-03-13 2019-07-19 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona para utilização no tratamento de cancro
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
CA2912518A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated Regulation of cancer using natural compounds and/or diet
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS AND METHODS OF USE FOR SELECTIVE DRUG DELIVERY
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) * 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2014206466A1 (en) 2013-06-26 2014-12-31 Afg Technologies S.À.R.L Screening, diagnosis, prognostication and treatment of ovarian cancer
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
WO2015017729A1 (en) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
US20160166637A1 (en) 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
SG11201601416VA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Novel sez6 modulators and methods of use
US20150072021A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
US20150093331A1 (en) 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US9878049B2 (en) 2013-10-09 2018-01-30 The University Of Akron High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2015061372A1 (en) 2013-10-21 2015-04-30 Hemoshear, Llc In vitro model for a tumor microenvironment
US9783549B2 (en) 2013-11-04 2017-10-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CA2929715A1 (en) 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
ES2895600T3 (es) 2013-11-15 2022-02-22 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso de la misma en terapia de combinación
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9303039B2 (en) 2013-12-06 2016-04-05 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
WO2015095784A1 (en) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
EP3092254A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating her2 positive tumors
EP3092027A4 (en) 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
CN109316605B (zh) 2014-01-20 2023-07-14 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
CA3008111C (en) 2014-02-03 2019-09-24 Eidgenoessische Technische Hochschule Zurich Low molecular weight drug conjugates for binding to carbonic anhydrase ix
KR20160136279A (ko) * 2014-02-03 2016-11-29 국립연구개발법인 고쿠리츠간켄큐센터 항-조직 인자 모노클로널 항체
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
US9260478B2 (en) * 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
AU2015243537B2 (en) 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics
US20170035894A1 (en) 2014-04-14 2017-02-09 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2015195925A1 (en) * 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
EP3069734A1 (en) * 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CN107921144B (zh) 2015-06-20 2023-11-28 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物

Also Published As

Publication number Publication date
US20180193478A1 (en) 2018-07-12
NZ744808A (en) 2024-04-26
AU2017225982B2 (en) 2023-10-05
PH12018501847A1 (en) 2019-05-15
TW201800110A (zh) 2018-01-01
UA125024C2 (uk) 2021-12-29
ES2880402T3 (es) 2021-11-24
AR121301A2 (es) 2022-05-04
MX2023003808A (es) 2023-04-12
KR20180115330A (ko) 2018-10-22
EP3423105A1 (en) 2019-01-09
JP2019516664A (ja) 2019-06-20
IL261428A (en) 2018-10-31
SI3423105T1 (sl) 2021-12-31
AU2023285804A1 (en) 2024-01-18
CN114191563A (zh) 2022-03-18
TWI772288B (zh) 2022-08-01
CN114272389A (zh) 2022-04-05
JOP20210073A1 (ar) 2023-01-30
DK3423105T3 (da) 2021-07-26
CL2021000048A1 (es) 2021-05-28
SG11201806515RA (en) 2018-09-27
WO2017151979A1 (en) 2017-09-08
JP7254861B2 (ja) 2023-04-10
JOP20210074A1 (ar) 2023-01-30
CN114191428B (zh) 2024-09-24
TWI825834B (zh) 2023-12-11
CN114272389B (zh) 2023-04-18
US20200297860A1 (en) 2020-09-24
KR20240007722A (ko) 2024-01-16
JP7556086B2 (ja) 2024-09-25
AU2017225982A1 (en) 2018-08-16
MA45280B1 (fr) 2021-08-31
CL2021000049A1 (es) 2021-05-28
CA3013791A1 (en) 2017-09-08
MA45280A (fr) 2019-01-09
CL2018002456A1 (es) 2018-12-21
IL292946B1 (en) 2024-07-01
JP2023082096A (ja) 2023-06-13
MX2023003806A (es) 2023-04-12
PE20181953A1 (es) 2018-12-17
BR112018067379A2 (pt) 2019-01-15
RU2018134331A3 (es) 2020-08-14
CN114191428A (zh) 2022-03-18
SG10202007520WA (en) 2020-09-29
TW202241524A (zh) 2022-11-01
JOP20170053B1 (ar) 2021-08-17
MY189113A (en) 2022-01-26
MD3423105T2 (ro) 2021-10-31
RU2018134331A (ru) 2020-04-02
KR20220101203A (ko) 2022-07-19
CN108883198B (zh) 2022-08-09
KR20220101204A (ko) 2022-07-19
CO2018008667A2 (es) 2018-08-31
US10548986B2 (en) 2020-02-04
CN108883198A (zh) 2018-11-23
RU2754369C2 (ru) 2021-09-01
IL292946A (en) 2022-07-01
PT3423105T (pt) 2021-07-19
KR102445255B1 (ko) 2022-09-22
KR102456433B1 (ko) 2022-10-19
US20170252458A1 (en) 2017-09-07
KR102702620B1 (ko) 2024-09-05
LT3423105T (lt) 2021-09-10
JP6599019B2 (ja) 2019-10-30
US20230398228A1 (en) 2023-12-14
AR107787A1 (es) 2018-06-06
JP2020128413A (ja) 2020-08-27
PL3423105T3 (pl) 2021-10-25
JP2021185176A (ja) 2021-12-09
CY1124628T1 (el) 2022-07-22
TW202408592A (zh) 2024-03-01
JP2020019787A (ja) 2020-02-06
EP3824909A1 (en) 2021-05-26
PE20231049A1 (es) 2023-07-11
JP6870051B2 (ja) 2021-05-12
HRP20211125T1 (hr) 2021-10-15
RU2021125492A (ru) 2022-04-05
RS62108B1 (sr) 2021-08-31
EP3423105B1 (en) 2021-05-05
HUE054726T2 (hu) 2021-09-28
US10322192B2 (en) 2019-06-18
MX2023003809A (es) 2023-04-12
AR121302A2 (es) 2022-05-04
MX2018010562A (es) 2019-02-20

Similar Documents

Publication Publication Date Title
PE20231050A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
WO2017089890A8 (en) Conjugates comprising self-immolative groups and methods related thereto
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
CL2017001916A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016)
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
AR091703A1 (es) Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
BR112017022258A2 (pt) conjugados de anticorpo-droga sítio-específicos
CR8568A (es) Macrolidos y metodos para producir los mismos
PA8626201A1 (es) Conjugados de caliqueamicina
HN2006019066A (es) "(s)-n-metilnaltrexona"
DOP2010000014A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
AR102105A1 (es) Conjugado radiofarmacéutico
GT200900035A (es) Anticuerpo especifico prlr y sus usos
AR112015A1 (es) Composiciones sólidas para administración oral
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
CL2009000275A1 (es) Compuestos derivados de furo [3,2-c]piridina y tieno [3,2-c] piridina; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.